Vir’s VIR-2482 Flunks In Phase II As Company Shifts Focus To Other Programs
Negative results from the PENINSULA study cast doubt on a Phase Ib study of the antibody in elderly adults. The company unveiled its next-generation flu drug, VIR-2981.
Negative results from the PENINSULA study cast doubt on a Phase Ib study of the antibody in elderly adults. The company unveiled its next-generation flu drug, VIR-2981.